Quince Therapeutics (QNCX) Total Current Liabilities (2018 - 2026)
Quince Therapeutics (QNCX) posted quarterly Total Current Liabilities of $8.8 million for Q1 2026, up 4.93% year-over-year from $8.4 million in Q1 2025, and down 79.72% quarter-over-quarter from $43.2 million in Q4 2025.
Quince Therapeutics (QNCX) Total Current Liabilities (2018 - 2026) Analysis & Trends
Quince Therapeutics' Total Current Liabilities history runs 9 years deep, the most recent figure standing at $8.8 million for Q1 2026.
- In Q1 2026, Total Current Liabilities rose 4.93% year-over-year to $8.8 million; the TTM figure through Mar 2026 stood at $8.8 million (up 4.93% YoY), while the FY2025 annual figure was $43.2 million, up 493.93% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $8.8 million, down from $43.2 million in the prior quarter.
- The five-year high for Total Current Liabilities was $43.2 million in Q4 2025, with the low at $2.0 million in Q2 2023.
- The 5-year median for Total Current Liabilities is $7.5 million (2025), against an average of $9.8 million.
- The sharpest annual moves came in 2022 and 2025: Total Current Liabilities tumbled 78.42% in 2022, then jumped 493.93% in 2025.
- Quince Therapeutics' Total Current Liabilities stood at $3.1 million in 2022, then soared by 211.89% to $9.6 million in 2023, then dropped by 23.97% to $7.3 million in 2024, then surged by 493.93% to $43.2 million in 2025, then tumbled by 79.72% to $8.8 million in 2026.
- Business Quant data shows QNCX's Total Current Liabilities at $8.8 million in Q1 2026, $43.2 million in Q4 2025, and $26.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 630.93 Mn |
| 10 | Quince Therapeutics | 203.43 Mn | 203.43 Mn | - | 8.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.77 Mn |
| Dec 31, 2025 | 43.23 Mn |
| Sep 30, 2025 | 26.04 Mn |
| Jun 30, 2025 | 7.47 Mn |
| Mar 31, 2025 | 8.36 Mn |
| Dec 31, 2024 | 7.28 Mn |
| Sep 30, 2024 | 5.43 Mn |
| Jun 30, 2024 | 10.32 Mn |
| Mar 31, 2024 | 9.84 Mn |
| Dec 31, 2023 | 9.57 Mn |
| Sep 30, 2023 | 2.25 Mn |
| Jun 30, 2023 | 1.95 Mn |
| Mar 31, 2023 | 3.12 Mn |
| Dec 31, 2022 | 3.07 Mn |
| Sep 30, 2022 | 4.95 Mn |
| Jun 30, 2022 | 5.95 Mn |
| Mar 31, 2022 | 9.71 Mn |
| Dec 31, 2021 | 14.22 Mn |
| Sep 30, 2021 | 14.15 Mn |
| Jun 30, 2021 | 18.54 Mn |